Rosetta Genomics Announces Exercise and Closing of Underwriter's Over-Allotment Option

Rosetta Genomics Ltd. ("Rosetta")

, a leading developer and provider of microRNA-based molecular diagnostics, today announced the sale of an additional 825,000 ordinary shares pursuant to the exercise by the underwriter of the over-allotment option granted to the underwriter in connection with Rosetta's recent public offering of 5.5 million ordinary shares at a price to the public of $5.00 per share.  The gross proceeds to Rosetta from the offering, including the exercise of the over-allotment option, were approximately $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by Rosetta. Aegis Capital Corp. acted as the sole book-running manager for the offering. A registration statement on Form F-1 relating to the shares was filed with the Securities and Exchange Commission (the "SEC") and was declared effective on August 2, 2012.  A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov.  Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC